Medpace Holdings, Inc. (NASDAQ: MEDP) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 33.97 | EPS (ttm) | 17.39 | Insider Own | 47.45% | Shs Outstand | 27.91M | Perf Week | 2.35% |
| Market Cap | 16.49B | Forward P/E | 30.53 | EPS next Y | 19.35 | Insider Trans | -0.47% | Shs Float | 22.50M | Perf Month | 10.30% |
| Enterprise Value | 16.10B | PEG | 1.31 | EPS next Q | 4.39 | Inst Own | - | Short Float | 9.74% | Perf Quarter | 37.78% |
| Income | 484.71M | P/S | 5.93 | EPS this Y | 3.12% | Inst Trans | - | Short Ratio | 5.86 | Perf Half Y | 9.13% |
| Sales | 2.78B | P/B | 38.54 | EPS next Y | 9.92% | ROA | 23.89% | Short Interest | 2.19M | Perf YTD | 5.17% |
| Book/sh | - | P/C | 22.22 | EPS next 5Y | 10.62% | ROE | 110.15% | 52W High | 684.79 -12.87% | Perf Year | 37.25% |
| Cash/sh | - | P/FCF | 22.48 | EPS past 3/5Y | 28.04% 31.81% | ROIC | 77.00% | 52W Low | 376.77 58.36% | Perf 3Y | 131.37% |
| Dividend Est. | - | EV/EBITDA | 26.74 | Sales past 3/5Y | 20.11% 22.26% | Gross Margin | 28.76% | Volatility | 2.39% 3.58% | Perf 5Y | 235.72% |
| Dividend TTM | - | EV/Sales | 5.79 | EPS Y/Y TTM | 35.15% | Oper. Margin | 20.97% | ATR (14) | 21.52 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.73 | Sales Y/Y TTM | 31.91% | Profit Margin | 17.67% | RSI (14) | 63.88 | Recom | 2.84 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.73 | EPS Q/Q | 37.10% | SMA20 | 4.74% | Beta | 1.12 | Target Price | 598.89 |
| Payout | 0.00% | Debt/Eq | 0.28 | Sales Q/Q | 17.25% | SMA50 | 13.65% | Rel Volume | 0.41 | Prev Close | 590.67 |
| Employees | 6,200 | LT Debt/Eq | 0.50 | Earnings | Oct 28 | SMA200 | 13.71% | Avg Volume | 331.95K | Price | 596.66 |
| IPO Date | Aug 11, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.84% 2.58% | Net Debt/EBITDA | -0.64 | Volume | 136,482 | Change | 1.01% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-24-26 | Reiterated | Robert W. Baird | $547 → $624 | |
| Jul-24-26 | Reiterated | Mizuho | Outperform | $586 → $665 |
| Jul-24-26 | Reiterated | RBC Capital | Outperform | $484 → $692 |
| Jul-24-26 | Reiterated | BMO Capital | Market Perform | $400 → $600 |
| Jul-23-26 | Reiterated | Barclays | Equal Weight | $450 → $600 |
| Jul-23-26 | Reiterated | Leerink Partners | Market Perform | $515 → $620 |
| Jul-23-26 | Reiterated | Deutsche Bank | Hold | $480 → $535 |
| Jul-13-26 | Reiterated | Mizuho | Outperform | $582 → $586 |
| Jul-08-26 | Reiterated | Robert W. Baird | $477 → $547 | |
| Jul-08-26 | Downgrade | Baird | Outperform → Neutral |
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,782 | 2,530 | 2,109 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,982 | 1,770 | 1,453 | — | — | — | — | — | — | |
| Gross Profit | 800 | 761 | 656 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 189 | 198 | 180 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 28 | 28 | 29 | — | — | — | — | — | — | |
| Operating Income | 584 | 535 | 447 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | 7 | 29 | — | — | — | — | — | — | |
| Net Income Before Taxes | 600 | 542 | 476 | — | — | — | — | — | — | |
| Income Taxes | 108 | 91 | 72 | — | — | — | — | — | — | |
| Consolidated Net Income | 491 | 451 | 404 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 491 | 451 | 404 | — | — | — | — | — | — | |
| Net Income | 491 | 451 | 404 | — | — | — | — | — | — | |
| EPS (Recurring) | 17.39 | 15.64 | 13.06 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 17.39 | 15.64 | 13.06 | — | — | — | — | — | — | |
| EPS (Diluted) | 17.07 | 15.28 | 12.63 | — | — | — | — | — | — | |
| EBITDA | 602 | 571 | 505 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 34.95 | 36.76 | 26.30 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.01 | 6.44 | 4.88 | — | — | — | — | — | — | |
| Gross Margin | 28.76 | 30.08 | 31.10 | — | — | — | — | — | — | |
| Operating Margin | 20.99 | 21.15 | 21.19 | — | — | — | — | — | — | |
| Net Margin | 17.65 | 17.83 | 19.16 | — | — | — | — | — | — | |
| Shares Outstanding | 28 | 29 | 31 | — | — | — | — | — | — | |
| Market Capitalization | 16,706 | 16,288 | 10,299 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Troendle August J. | President & CEO | Jul 28 '26 | Sale | 600.01 | 3,510 | 2,106,035 | 638,946 | Jul 29 |
| BURWIG SUSAN E | Exec. VP, Operations | Jul 28 '26 | Sale | 600.00 | 7,500 | 4,500,000 | 62,984 | Jul 29 |
| Troendle August J. | President & CEO | Jul 27 '26 | Sale | 600.85 | 3,728 | 2,239,969 | 642,456 | Jul 29 |
| Carley Brian T | Director | Jun 30 '26 | Option Exercise | 0.00 | 36 | 0 | 32,825 | Jul 02 |
| McCarthy Cornelius P. III | Director | Jun 30 '26 | Option Exercise | 0.00 | 28 | 0 | 10,352 | Jul 02 |
| EWALD STEPHEN P | General Counsel & Corp. Secy. | May 28 '26 | Option Exercise | 138.87 | 16,349 | 2,270,386 | 36,692 | Jun 01 |
| EWALD STEPHEN P | General Counsel & Corp. Secy. | May 28 '26 | Sale | 450.00 | 16,349 | 7,357,050 | 20,343 | Jun 01 |
| EWALD STEPHEN P | General Counsel & Corp. Secy. | Apr 24 '26 | Option Exercise | 138.87 | 3,500 | 486,045 | 20,343 | Apr 28 |
| Brady Kevin M. | CFO & Treasurer | Apr 24 '26 | Option Exercise | 138.87 | 7,000 | 972,090 | 12,830 | Apr 28 |
| Kraft Robert O. | Director | Mar 31 '26 | Option Exercise | 0.00 | 33 | 0 | 922 | Apr 02 |
| McCarthy Cornelius P. III | Director | Mar 31 '26 | Option Exercise | 0.00 | 29 | 0 | 10,324 | Apr 02 |
| Carley Brian T | Director | Mar 31 '26 | Option Exercise | 0.00 | 36 | 0 | 32,789 | Apr 02 |
| BURWIG SUSAN E | Exec. VP, Operations | Mar 18 '26 | Option Exercise | 166.73 | 12,000 | 2,000,760 | 70,484 | Mar 19 |
| GEIGER JESSE J | President | Mar 17 '26 | Option Exercise | 138.87 | 31,707 | 4,403,151 | 46,707 | Mar 19 |
| GEIGER JESSE J | President | Mar 17 '26 | Sale | 455.30 | 31,707 | 14,436,197 | 15,000 | Mar 19 |